Routine sessions pursuant to Section 63 German Medicines Act (AMG)
Routine sessions pursuant to Section 63 AMG take place at the BfArM at least twice a year, where graduated plan stakeholders (Stufenplanbeteiligte) exchange information about current problems of pharmaceutical safety. In accordance with Section 77a para 2 AMG, results and decisions, including transparencies of prepared talks, are recorded and published here, beginning with session 57.The following institutions are represented: Federal Institute for Drugs and Medical Devices (BfArM), Paul-Ehrlich Institute (PEI), Federal Office of Consumer Protection and Food Safety (BVL), Central Authority of the Laender for Health Protection with Regard to Medicinal Products and Medical Device (ZLG), Federal Ministry of Health (BMG), Federal Ministry of Defence (BMVg), Federal Ministry of Food, Agriculture and Consumer Protection (BMELV), drug comissions of the healing professions, associations of the pharmaceutical industry, patients’ representative, a representative of the pharmacovigilance centres.
The documents listed below are available in German only.